ReviewOncoTargets and therapy2018
Research progress on GP73 in malignant tumors.
Review in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- The role of GP73 in predicting overall survival and chemotherapy response in locally advanced gastric cancer: a retrospective cohort study.BMC gastroenterology · 2026Article
- Immunonutrients for radiation-induced oral mucositis in head and neck cancer: current evidence and future perspectives.Frontiers in immunology · 2026Review
- Development and validation of a GP73-based predictive model for the diagnosis of early-stage hepatocellular carcinoma.Journal of gastrointestinal oncology · 2025Article
- Current status and new directions for hepatocellular carcinoma diagnosis.Liver research (Beijing, China) · 2024Review
- Development of a diagnostic nomogram for alpha-fetoprotein-negative hepatocellular carcinoma based on serological biomarkers.World journal of gastrointestinal oncology · 2024Article
- Golgi protein 73: charting new territories in diagnosing significant fibrosis in MASLD: a prospective cross-sectional study.Frontiers in endocrinology · 2024Article
- Integrative Analysis Reveals the Potential Role and Prognostic Value of GOLM1 in Hepatocellular Carcinoma.Oxidative medicine and cellular longevity · 2022Article
- TCF11 Has a Potent Tumor-Repressing Effect Than Its Prototypic Nrf1α by Definition of Both Similar Yet Different Regulatory Profiles, With a Striking Disparity From Nrf2.Frontiers in oncology · 2021Article
- High GP73 Expression Correlates with Poor Response to Neoadjuvant Chemotherapy and Survival in Gastric Cancer: A Tissue Microarray Study.Pathology oncology research : POR · 2021Article
- Golgi protein 73, hepatocellular carcinoma and other types of cancers.Liver research (Beijing, China) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant cancer is one of the most serious diseases that currently endanger human health. As most tumors are diagnosed at an advanced stage, the current treatments show poor therapeutic efficacy, and the patients have poor prognosis. However, a 5-year survival rate higher than 80% could be achieved if tumors are diagnosed at an early stage. Therefore, early diagnosis and treatment play important roles in the prevention and treatment of malignant tumors, and serum tumor markers are important for the early diagnosis of malignant cancers. Recent studies have shown that GP73, a transmembrane protein, has greater diagnostic value in primary liver cancer than in other types of cancers, and research on the regulation of GP73 expression has unveiled broad prospects in anticancer targeted therapy. Thus, GP73, as a new tumor marker, deserves further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.